Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
- PMID: 24018263
- PMCID: PMC3837874
- DOI: 10.1128/AAC.01519-13
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Abstract
Although Clinical and Laboratory Standards Institute (CLSI) clinical breakpoints (CBPs) are available for interpreting echinocandin MICs for Candida spp., epidemiologic cutoff values (ECVs) based on collective MIC data from multiple laboratories have not been defined. While collating CLSI caspofungin MICs for 145 to 11,550 Candida isolates from 17 laboratories (Brazil, Canada, Europe, Mexico, Peru, and the United States), we observed an extraordinary amount of modal variability (wide ranges) among laboratories as well as truncated and bimodal MIC distributions. The species-specific modes across different laboratories ranged from 0.016 to 0.5 μg/ml for C. albicans and C. tropicalis, 0.031 to 0.5 μg/ml for C. glabrata, and 0.063 to 1 μg/ml for C. krusei. Variability was also similar among MIC distributions for C. dubliniensis and C. lusitaniae. The exceptions were C. parapsilosis and C. guilliermondii MIC distributions, where most modes were within one 2-fold dilution of each other. These findings were consistent with available data from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (403 to 2,556 MICs) for C. albicans, C. glabrata, C. krusei, and C. tropicalis. Although many factors (caspofungin powder source, stock solution solvent, powder storage time length and temperature, and MIC determination testing parameters) were examined as a potential cause of such unprecedented variability, a single specific cause was not identified. Therefore, it seems highly likely that the use of the CLSI species-specific caspofungin CBPs could lead to reporting an excessive number of wild-type (WT) isolates (e.g., C. glabrata and C. krusei) as either non-WT or resistant isolates. Until this problem is resolved, routine testing or reporting of CLSI caspofungin MICs for Candida is not recommended; micafungin or anidulafungin data could be used instead.
Similar articles
-
Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.Antimicrob Agents Chemother. 2014;58(2):916-22. doi: 10.1128/AAC.02020-13. Epub 2013 Nov 25. Antimicrob Agents Chemother. 2014. PMID: 24277027 Free PMC article.
-
Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.BMC Microbiol. 2015 May 20;15:106. doi: 10.1186/s12866-015-0442-4. BMC Microbiol. 2015. PMID: 25990252 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.J Clin Microbiol. 2010 May;48(5):1592-9. doi: 10.1128/JCM.02445-09. Epub 2010 Mar 24. J Clin Microbiol. 2010. PMID: 20335424 Free PMC article.
-
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24. Drug Resist Updat. 2011. PMID: 21353623 Review.
Cited by
-
Inter-laboratory variability of caspofungin MICs for Nakaseomyces glabrata isolates - an Irish tertiary hospital experience.Access Microbiol. 2023 Oct 9;5(10):000617.v4. doi: 10.1099/acmi.0.000617.v4. eCollection 2023. Access Microbiol. 2023. PMID: 37970072 Free PMC article.
-
Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins.Mycopathologia. 2016 Oct;181(9-10):663-70. doi: 10.1007/s11046-016-0028-1. Epub 2016 Jun 18. Mycopathologia. 2016. PMID: 27318852
-
Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.J Clin Microbiol. 2014 Jan;52(1):108-14. doi: 10.1128/JCM.02481-13. Epub 2013 Oct 23. J Clin Microbiol. 2014. PMID: 24153129 Free PMC article.
-
Deciphering Candida auris Paradoxical Growth Effect (Eagle Effect) in Response to Echinocandins.Methods Mol Biol. 2022;2517:73-85. doi: 10.1007/978-1-0716-2417-3_6. Methods Mol Biol. 2022. PMID: 35674946
-
Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.Antimicrob Agents Chemother. 2015;59(6):3570-3. doi: 10.1128/AAC.04922-14. Epub 2015 Mar 16. Antimicrob Agents Chemother. 2015. PMID: 25779577 Free PMC article.
References
-
- Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonheyder HC, Knudsen JD, Jensen IM. 2008. Seminational surveillance of fungemia in Denmark 2004–2006: increasing incidence of fungemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487–494 - PubMed
-
- Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Filler SG, Fischer JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503–535 - PMC - PubMed
-
- Barnes PD, Marr KA. 2007. Risk, diagnosis and outcome of invasive fungal infections in haematopoietic stem cell transplant recipients. Br. J. Haematol. 139:519–531 - PubMed
-
- Clinical and Laboratory Standards Institute 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA
-
- Clinical and Laboratory Standards Institute 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous